EUVIMEDEUVIMED entdecken
Open Access

Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis

Napon Hiranburana iD, Jiratchaya Sophonphan iD, Stephen J Kerr iD, Cheewanan Lertpiriyasuwat iD, Sairat Noknoy iD, Supunnee Jirajariyavej iD, Chris Fujitnirun, Ploenchan Chetchotisakd iD, Rangsima Lolekha, Chureeratana Bowonwatanuwong iD, Kiat Ruxrungtham iD, Opass Putcharoen iD und 1 weitere

HIV Medicine · 2025

DOI: 10.1111/hiv.70178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Napon Hiranburana und 12 weiteren Autor:innen. Beteiligte Einrichtung: HIVNAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Piperazines, Pyridones, HIV Infections. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAAA NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate real‐world outcomes of dolutegravir (DTG)‐based first‐line antiretroviral therapy (ART) among people with HIV in Thailand, where baseline HIV‐1 RNA and resistance testing is not routinely available.

Methods

This retrospective cohort study enrolled ART‐naive Thai people with HIV aged ≥15 years who initiated DTG‐based ART between 2020 and 2023 under the national Universal Health Coverage programme. People with HIV with ≥1 post‐baseline HIV viral load (VL) measurement were included. Virological non‐suppression (VNS) was defined as VL ≥1000 copies/mL after ≥6 months of ART. The primary outcome was the proportion achieving virological suppression (VL

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingPiperazinesPyridonesHIV InfectionsOxazinesHIV Integrase InhibitorsAnti-HIV AgentsHumansMaleThailandFemaleAdultRetrospective StudiesViral LoadMiddle AgedAdolescentYoung AdultHIV-1Sustained Virologic ResponseCD4 Lymphocyte CountTreatment Outcome

Stichwörter der Autor:innen

AsiaHIV‐1dolutegravirefficacylow‐ and middle‐income countries (LMICs)

Substanzen

Heterocyclic Compounds, 3-RingPiperazinesPyridonesOxazinesHIV Integrase InhibitorsAnti-HIV Agents

Autor:innen und Institutionen

  • HIVNAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand.
  • Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Division of AIDS and STI, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
  • Taksin Hospital, Bangkok, Thailand.

ORCID-Profile: Napon Hiranburana, Jiratchaya Sophonphan, Stephen J Kerr, Cheewanan Lertpiriyasuwat, Sairat Noknoy, Supunnee Jirajariyavej, Ploenchan Chetchotisakd, Chureeratana Bowonwatanuwong, Kiat Ruxrungtham, Opass Putcharoen, Anchalee Avihingsanon

Förderung

  • NHLBI NIH HHS
  • NIAAA NIH HHS
  • NIMH NIH HHS
  • U.S. National Institute of Health's (NIH) National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • NIDDK NIH HHS
  • NIDA NIH HHS
  • FIC NIH HHS

Zitieren

APA

Hiranburana, N., Sophonphan, J., Kerr, S. J., Lertpiriyasuwat, C., Noknoy, S., Jirajariyavej, S., Fujitnirun, C., Chetchotisakd, P., Lolekha, R., Bowonwatanuwong, C., Ruxrungtham, K., Putcharoen, O., & Avihingsanon, A. (2025). Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis. HIV Medicine. https://doi.org/10.1111/hiv.70178

Vancouver

Hiranburana N, Sophonphan J, Kerr SJ, Lertpiriyasuwat C, Noknoy S, Jirajariyavej S, et al. Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis. HIV Medicine. 2025. doi:10.1111/hiv.70178

BibTeX
@article{Hiranburana2025,
  author = {Hiranburana, Napon and Sophonphan, Jiratchaya and Kerr, Stephen J and Lertpiriyasuwat, Cheewanan and Noknoy, Sairat and Jirajariyavej, Supunnee and Fujitnirun, Chris and Chetchotisakd, Ploenchan and Lolekha, Rangsima and Bowonwatanuwong, Chureeratana and Ruxrungtham, Kiat and Putcharoen, Opass and Avihingsanon, Anchalee},
  title = {Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70178}
}
Kostenlos starten →